MedPath

Multidisciplinary Association For Psychedelic Studies, Inc.

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
3 (100.0%)

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

Phase 2
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
First Posted Date
2016-05-03
Last Posted Date
2023-07-12
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Target Recruit Count
80
Registration Number
NCT02759185
Locations
πŸ‡ΊπŸ‡Έ

Scottsdale Research Institute, Phoenix, Arizona, United States

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Phase 2
Withdrawn
Conditions
Stage IV Melanoma
Anxiety
Interventions
First Posted Date
2009-09-18
Last Posted Date
2023-12-26
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Registration Number
NCT00979693
Locations
πŸ‡ΊπŸ‡Έ

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

Phase 2
Completed
Conditions
Anxiety
Interventions
First Posted Date
2009-06-15
Last Posted Date
2023-07-12
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Target Recruit Count
12
Registration Number
NCT00920387
Locations
πŸ‡¨πŸ‡­

Private Practices of Peter Gasser MD, Solothurn, Switzerland

News

FDA Approves Cannabis Study for PTSD in Veterans, Potentially Boosting Cannabis Stocks

The FDA has approved a study examining cannabis's therapeutic effects on 320 veterans with moderate to severe PTSD, a condition affecting roughly 7% of U.S. veterans.

FDA Approves Landmark Cannabis Study for PTSD Treatment in Veterans

The FDA has approved a study examining cannabis's therapeutic potential for treating post-traumatic stress disorder (PTSD) in 320 veterans.

FDA Approves Phase 2 Clinical Trial of Smoked Marijuana for PTSD in Veterans

The FDA has approved a Phase 2 clinical trial to evaluate smoked marijuana for treating PTSD in veterans, funded by Michigan cannabis sales tax revenue.

FDA Clears Phase 2 Trial of Smoked Cannabis for PTSD in Veterans

The FDA has cleared a Phase 2 trial to evaluate smoked cannabis in 320 veterans with moderate-to-severe PTSD who have prior cannabis use.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.